Biogen has announced a new plan it calls Fit for Growth, which will reduce its net operating expenses by about $700 million. Biogen plans to cut about 1,000 jobs—11% of its total—by 2025. In a press release, CEO Christopher A. Viehbacher describes the firm’s business as being “in transition.” Viehbacher joined the company to help it refocus after the failure of the Alzheimer’s disease drug Aduhelm.
I think I'm going to be watching for pharma and chemical manufacturer job cuts over the next 6-12 months to see if there are trends developing. That being said, this seems to be more specific to Biogen and the impacts of Aduhelm.
No comments:
Post a Comment
looks like Blogger doesn't work with anonymous comments from Chrome browsers at the moment - works in Microsoft Edge, or from Chrome with a Blogger account - sorry! CJ 3/21/20